Karen Akinsanya sold $420k of SDGR
President of R&D, Therapeutics at Schrodinger, Inc.. 16,723 shares at an average of $25.09, traded Apr 14, 2025, filed Apr 15, 2025.
Score components
- +20RolePresident
- +16Trade size$420k at market
- +20Share of holdings soldSold 52% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.7%, 3m -20.4%, 6m -24.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001490978-25-000036, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 14, 2025 | MOption exercise Common Stock10b5-1 | +13,378 | $3.22 | $43k | 29,003 | Apr 15, 2025 |
| Apr 14, 2025 | MOption exercise Common Stock10b5-1 | +3,345 | $2.92 | $9,767 | 32,348 | Apr 15, 2025 |
| Apr 14, 2025 | SOpen-market sale Common Stock10b5-1 | -8,378 | $25.11 | $210k | 23,970 | Apr 15, 2025 |
| Apr 14, 2025 | SOpen-market sale Common Stock10b5-1 | -5,000 | $25.11 | $126k | 18,970 | Apr 15, 2025 |
| Apr 14, 2025 | SOpen-market sale Common Stock10b5-1 | -3,345 | $25.00 | $84k | 15,625 | Apr 15, 2025 |
| Apr 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -13,378 | $0.00 | $0 | 0 | Apr 15, 2025 |
| Apr 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,345 | $0.00 | $0 | 0 | Apr 15, 2025 |
Related signals
Other insiders at Schrodinger, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | Schrodinger, Inc. | Karen Akinsanya See Remarks | $928k 31,599 shares | -31% | |
| 2Weak | Schrodinger, Inc. | Rachit Jain EVP & CFO | $14k 875 shares | -2% | |
| 28Weak | Schrodinger, Inc. | Ramy Farid President & CEO | $1.1M 86,000 shares | -23% | |
| 10Weak | Schrodinger, Inc. | Rachit Jain EVP & CFO | $11k 844 shares | -2% | |
| 10Weak | Schrodinger, Inc. | Robert Lorne Abel See Remarks | $17k 1,300 shares | -2% | |
| 10Weak | Schrodinger, Inc. | Karen Akinsanya See Remarks | $18k 1,366 shares | -2% | |
| 26Weak | Schrodinger, Inc. | Ramy Farid President & CEO | $47k 3,661 shares | -1% | |
| 10Weak | Schrodinger, Inc. | Jenny Herman CAO | $18k 1,383 shares | -4% | |
| 17Weak | Schrodinger, Inc. | Rachit Jain EVP & CFO | $21k 1,631 shares | -3% | |
| 15Weak | Schrodinger, Inc. | Kenneth Patrick Lorton EVP, CTO & COO, Software | $16k 1,222 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.